Tharimmune Inc’s stock price surged 207% after the biotech firm announced positive clinical results for its lead cancer treatment candidate, TH104, which targets ferroptosis.

Tharimmune Inc’s stock price surged 206% in a single day after announcing positive simulation results for its lead clinical candidate, TH104, a potential treatment for respiratory depression caused by fentanyl and other opioids.

Tharimmune Inc is a biotech company pioneering cancer treatment with its novel therapeutic candidates targeting ferroptosis, showing promising clinical data and potential to redefine cancer therapy.

Tharimmune Inc, a biotech company pioneering the development of ferroptosis-based cancer treatments, is navigating the challenges of the industry while holding promise for transforming cancer treatment.

Tharimmune Inc. has received FDA approval for its opioid countermeasure, TH104, a buccal film formulation designed to prevent respiratory and nervous system depression in individuals exposed to high-potency opioids.